These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 15546725

  • 1. Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.
    Duan D, Li Z, Luo H, Zhang W, Chen L, Xu X.
    Bioorg Med Chem Lett; 2004 Dec 20; 14(24):6041-4. PubMed ID: 15546725
    [Abstract] [Full Text] [Related]

  • 2. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Dec 20; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 3. A review of HCV protease inhibitors.
    Chen KX, Njoroge FG.
    Curr Opin Investig Drugs; 2009 Aug 20; 10(8):821-37. PubMed ID: 19649927
    [Abstract] [Full Text] [Related]

  • 4. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY, Lu CS, Lin TH.
    J Mol Graph Model; 2008 Apr 20; 26(7):1131-44. PubMed ID: 18024210
    [Abstract] [Full Text] [Related]

  • 5. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D.
    J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850
    [Abstract] [Full Text] [Related]

  • 7. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS.
    Acc Chem Res; 2008 Oct 25; 41(10):1252-63. PubMed ID: 18681464
    [Abstract] [Full Text] [Related]

  • 8. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinàs-Brunet M, Nar H, Lamarre D.
    Angew Chem Int Ed Engl; 2003 Mar 28; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract] [Full Text] [Related]

  • 9. Potent inhibitors of HCV-NS3 protease derived from boronic acids.
    Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem Lett; 2009 Jan 01; 19(1):180-3. PubMed ID: 19022670
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 11. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M, Francesco ME, Koch U, Liverton NJ, Summa V.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2574-8. PubMed ID: 19328685
    [Abstract] [Full Text] [Related]

  • 12. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX, Njoroge FG.
    Prog Med Chem; 2010 May 01; 49():1-36. PubMed ID: 20855037
    [No Abstract] [Full Text] [Related]

  • 13. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO, Bäck M, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5136-51. PubMed ID: 16675222
    [Abstract] [Full Text] [Related]

  • 14. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA, Rudd MT, Nguyen KT, McIntyre CJ, Romano JJ, Bush KJ, Varga SL, Ross CW, Carroll SS, DiMuzio J, Stahlhut MW, Olsen DB, Lyle TA, Vacca JP, Liverton NJ.
    Angew Chem Int Ed Engl; 2008 Aug 01; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract] [Full Text] [Related]

  • 15. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
    Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R, Benhar I.
    J Mol Biol; 2005 Apr 15; 347(5):991-1003. PubMed ID: 15784258
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM, Bailey MD, Beaulieu PL, Brochu C, Duceppe JS, Ferland JM, Ghiro E, Gorys V, Halmos T, Kawai SH, Poirier M, Simoneau B, Tsantrizos YS, Llinàs-Brunet M.
    Org Lett; 2004 Aug 19; 6(17):2901-4. PubMed ID: 15330643
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT, Zhang X, Huang PP, Klein LL, Kurtz KA, Konstantinidis AK, He W, Kati WM, Kempf DJ.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2745-50. PubMed ID: 18375121
    [Abstract] [Full Text] [Related]

  • 18. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R, Abid K, Pichardo J, Pazienza V, Ingravallo P, Kong R, Agrawal S, Bogen S, Saksena A, Cheng KC, Prongay A, Njoroge FG, Baroudy BM, Negro F.
    J Antimicrob Chemother; 2007 Jan 15; 59(1):51-8. PubMed ID: 17151003
    [Abstract] [Full Text] [Related]

  • 19. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Madison V, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2151-5. PubMed ID: 20226659
    [Abstract] [Full Text] [Related]

  • 20. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.
    J Viral Hepat; 2012 Feb 01; 19(2):e81-8. PubMed ID: 22239530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.